Fewer PSA Tests May Cut Overdiagnosis But Miss Aggressive Prostate Cancer Cases
The incidence of more aggressive prostate cancer cases that are higher-grade disease and metastasis at diagnosis have risen.
Category: Prostate
Prostate
Latest
Prostate
Latest
PSA Testing Rates Increased After National Guidelines Revised
In a large study, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions by the USPSTF on screening.
Prostate
Latest
FDA Has Authorized Software That Can Assist Prostate Cancer Diagnosis
The U.S. Food and Drug Administration (FDA) has authorized marketing of software to assist medical pathologists in detecting areas suspicious for cancer.
Propella Therapeutics, National Cancer Institute to Develop Treatment for Metastatic Prostate Cancer
Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate as a new therapy for metastatic prostate cancer.
Read More
Study: New Prostate Cancer Test Could Avoid Unnecessary Biopsies
A urine test could have avoided one-third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study.
Read More
Study Validates Ability of Myriad Genetics’ Prolaris Test to Guide Treatment for Prostate Cancer
The Prolaris test can more accurately predict the aggressiveness of prostate cancer allowing for more precise treatment and avoidance of more intense therapies with a patient’s parallel morbidities.
Read More
Decipher Prostate Test Clinically Validated as Predictor of Overall Survival
The study validated the Decipher RP test as an independent predictor of distant metastases, prostate cancer-specific mortality, and overall survival.
Read More
Veracyte to Acquire Decipher Biosciences
Decipher’s comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.
Read More
Research Detects HULLK in Prostate Cancer
The study data provides a potential new approach to early detection of prostate cancer and an alternative to invasive biopsies.
Read More
Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer
Medicare expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza (olaparib).
Read More
miR Scientific Noninvasive Prostate Cancer Test Validation Published
miR Scientific’s urine-based, noninvasive cancer test can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%.
Read More
Artificial Intelligence Identifies Prostate Cancer With Near-Perfect Accuracy
A study demonstrates the highest accuracy to date in recognizing and characterizing prostate cancer using an artificial intelligence program.
Read More
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More
Prolaris Predicts Which Prostate Cancer Patients Will Benefit from Multimodality Therapy
Prostate cancer patients above the high-risk threshold with a Prolaris score greater than 2.112 saw a statistically significant benefit from multimodality therapy.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Decipher Prostate RP Identifies Prostate Cancer Patients Likely to Benefit from Hormonal Therapy
Prostate cancer patients with Decipher high-risk scores received greater benefit from hormonal therapy than those with Decipher low-risk scores.
Read More
Molecular Subtyping Signature Predicts Benefit from Chemotherapy in Men with Metastatic Prostate Cancer
A Decipher GRID molecular subtyping signature successfully predicted which patients with mHSPC benefited from adding chemotherapy to androgen deprivation hormone therapy.
Read More
System Distinguishes Protein Expression Patterns from Two Prostate Cancer Types
Study data demonstrate the ability of the Adapt system to differentiate exosomes from cancer cell subtypes from the same tumor type.
Read More